Spinout named a ‘Fierce 15’ Biotech Companies of 2022 University of Dundee spinout Amphista Therapeutics has been designated as one of the world’s most promising biotechnology companies. University of Dundee spinout Amphista Therapeutics has been designated as one of the…
Researchers from the University of Dundee have discovered a small molecule that helps to eliminate a Parkinson’s disease-causing protein. Parkinson’s disease is a progressive neurodegenerative disorder affecting more than 10 million people worldwide. No cure is available and current treatment…
Now published in Chemical Society Reviews: Claudia & Alessio’s review on VHL ligands and their use as VHL inhibitors and in PROTAC degraders. Read the full article open access. Authors: Claudia J. Diehl, Alessio Ciulli* Title: Discovery of small molecule…
The University of Dundee and Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents, will partner to commercialise technology developed at Dundee that enhances the understanding of undruggable diseases. Bio-Techne has signed an exclusive licencing agreement to…
Early career researchers in the School have received support from the Scottish Universities Life Sciences Alliance (SULSA) to establish new life sciences networks by providing funds towards the running of a network event. Valentina Spiteri, Charlotte Crowe, and Mark Nakasone,…
Professor Alessio Ciulli has been awarded a European Federation for Medicinal Chemistry and Chemical Biology Awards 2022. He has been named the winner of the 2022 Prous Institute – Overton and Meyer Award for New Technologies in Drug Discovery. This…
University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion. As part of separate partnerships, Amphista will collaborate with Merck Healthcare and Bristol Myers Squibb to leverage…
Dr Xingui Liu has been awarded a Marie Skłodowska-Curie Fellowship to undertake research in the lab of Professor Alessio Ciulli in the newly established Centre for Targeted Protein Degradation (CeTPD). Dr Xingui Liu has been awarded a Marie Skłodowska-Curie Fellowship…
Targeted protein degradation (TPD) is an innovative field that is revolutionising drug development, with various modalities being explored by researchers to tackle undruggable targets and treat a wide range of diseases, including cancer, neurological disorders, and skin diseases. In this…
Tom & Conner’s review on Targeting Epigenetic Modulators Using PROTAC Degraders is now published in BMCL Great review article by Tom and Conner Read the full article. Authors: Thomas Webb, Conner Craigon, Alessio Ciulli* Title: Targeting Epigenetic Modulators Using PROTAC Degraders: Current Status…